P
Paramount Peptides
Request Full Data Access to the Medutest database of peptide tests.
Products examined
| Product | Rating | Samples | Avg | Min | Max | Latest |
|---|---|---|---|---|---|---|
| Ipamorelin | A | 7 | 8.2 | 6.5 | 9.5 | 27 Feb 2025 |
| PT-141 | C | 3 | 8.0 | 4.7 | 9.8 | 25 Apr 2025 |
| Semaglutide | C | 9 | 6.3 | 4.6 | 8.9 | 14 Jan 2025 |
| Retatrutide | C | 12 | 7.5 | 4.3 | 9.3 | 14 Jan 2025 |
| Survodutide | C | 3 | 5.2 | 4.6 | 6.0 | 25 Apr 2025 |
| BPC-157 | D | 11 | 6.8 | 3.2 | 9.0 | 14 Jan 2025 |
| Tirzepatide | D | 11 | 6.8 | 3.6 | 8.9 | 14 Jan 2025 |
| CJC-1295 | E | 9 | 4.9 | 2.2 | 6.8 | 14 Jan 2025 |
| 17a-Methyl-1-Testosterone | A | 6 | 7.2 | 4.3 | 9.4 | 23 May 2026 |
| 4-Anilinopiperidine CAS 99918-43-1 | A | 6 | 6.5 | 3.6 | 7.9 | 25 May 2026 |
| Adipotide | X | 1 | 5.2 | 5.2 | 5.2 | 14 Jan 2025 |
| Alprostadil | X | 1 | 6.9 | 6.9 | 6.9 | 6 May 2025 |
| APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 | A | 6 | 7.1 | 3.7 | 9.6 | 24 May 2026 |
| Boldenone Undecylenate (EQ) Raw | A | 3 | 7.8 | 6.8 | 8.6 | 24 May 2026 |
| BPC 500mcg + TB500 500mcg Blend Oral | A | 6 | 6.5 | 5.5 | 8.3 | 25 May 2026 |
| Cagrilintide 5mg + Semaglutide 5mg Blend | A | 6 | 7.1 | 5.0 | 10.0 | 23 May 2026 |
| Cerebrolysin | A | 6 | 6.0 | 5.4 | 7.7 | 24 May 2026 |
| CJC-1295 w/o DAC 10mg + IPA 10mg Blend | A | 2 | 6.5 | 6.2 | 6.7 | 24 May 2026 |
| DHB (1-Test Cyp) Oral | X | 1 | 6.2 | 6.2 | 6.2 | 7 May 2025 |
| DNP | A | 5 | 6.1 | 4.7 | 7.9 | 20 May 2026 |
| GHRP-2 Acetate | A | 6 | 7.4 | 5.5 | 9.5 | 25 May 2026 |
| GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | A | 4 | 6.8 | 6.1 | 8.1 | 17 May 2026 |
| HGH 191AA (Somatropin) | A | 5 | 6.4 | 5.3 | 7.4 | 20 May 2026 |
| Hyaluronic acid | A | 5 | 6.3 | 3.8 | 8.0 | 21 May 2026 |
| IGF-1 LR3 | A | 6 | 6.5 | 4.4 | 9.1 | 25 May 2026 |
| Ivermectin | A | 6 | 6.4 | 4.6 | 8.4 | 21 May 2026 |
| KLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg | A | 2 | 5.4 | 4.6 | 6.3 | 21 May 2026 |
| KPV Oral | A | 3 | 7.0 | 6.2 | 7.7 | 21 May 2026 |
| N-Acetyl Epitalon Amidate | A | 6 | 5.9 | 3.5 | 8.0 | 25 May 2026 |
| NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend | A | 2 | 7.2 | 4.5 | 10.0 | 20 May 2026 |
| Nandrolone Decanoate (Deca) Raw | X | 1 | 6.4 | 6.4 | 6.4 | 3 Jun 2025 |
| NPP (N-phenethyl-4-piperidone) CAS 39742-60-4 | A | 6 | 6.5 | 4.4 | 9.3 | 24 May 2026 |
| P21 | A | 3 | 7.4 | 7.0 | 7.6 | 17 May 2026 |
| PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 | A | 6 | 6.9 | 5.4 | 8.4 | 24 May 2026 |
| Retatrutide Raw | A | 3 | 7.1 | 4.1 | 10.0 | 21 May 2026 |
| Salbutamol | A | 3 | 6.9 | 6.1 | 7.4 | 24 May 2026 |
| Tesamorelin 11mg + Ipamorelin 6mg Blend | A | 6 | 7.3 | 4.8 | 9.0 | 24 May 2026 |
| Test Suspension | A | 4 | 6.0 | 5.2 | 7.0 | 23 May 2026 |
| Vesugen | A | 2 | 7.7 | 6.9 | 8.4 | 25 May 2026 |
| Vilon | A | 3 | 6.8 | 6.4 | 7.5 | 21 May 2026 |
The certificates
| Date | Product | Score | Declared | Measured | Deviation | Purity | Laboratory |
|---|---|---|---|---|---|---|---|
| 25 May 2026 | BPC 500mcg + TB500 500mcg Blend Oral | 6.9 | 100mg | 108.5mg | +8.5% | 97.01% | Lab A |
| 25 May 2026 | GHRP-2 Acetate | 6.9 | 15mg | 17.4mg | +15.9% | 98.34% | Lab D |
| 25 May 2026 | Ivermectin | 6.2 | 50mg | 46.2mg | -7.7% | 99.94% | Lab A |
| 25 May 2026 | NPP (N-phenethyl-4-piperidone) CAS 39742-60-4 | 5.4 | 100g | 93.0g | -7.0% | 98.19% | Lab D |
| 24 May 2026 | Adipotide | 7.1 | 20mg | 20.8mg | +4.2% | 99.48% | Lab E |
| 24 May 2026 | Cerebrolysin | 8.7 | 15mg | 15.0mg | -0.2% | 98.02% | Lab G |
| 24 May 2026 | HGH 191AA (Somatropin) | 5.9 | 50mg | 55.4mg | +10.8% | 97.50% | Lab G |
| 24 May 2026 | Vilon | 6.8 | 5mg | 5.0mg | +0.6% | 97.83% | Lab A |
| 24 May 2026 | GHRP-2 Acetate | 8.6 | 15mg | 17.0mg | +13.6% | 99.78% | Lab D |
| 24 May 2026 | GHRP-2 Acetate | 6.6 | 50mg | 48.5mg | -3.1% | 98.75% | Lab F |
| 24 May 2026 | 17a-Methyl-1-Testosterone | 8.6 | 20mg | 20.2mg | +1.1% | 95.61% | Lab G |
| 24 May 2026 | Cagrilintide 5mg + Semaglutide 5mg Blend | 7.2 | 30mg | 35.8mg | +19.2% | 99.21% | Lab C |
| 24 May 2026 | PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 | 8.8 | 500g | 590.4g | +18.1% | 99.84% | Lab D |
| 24 May 2026 | BPC 500mcg + TB500 500mcg Blend Oral | 5.1 | 10mg | 12.3mg | +22.9% | 98.02% | Lab D |
| 24 May 2026 | Cerebrolysin | 6.0 | 10mg | 8.8mg | -12.4% | 96.46% | Lab G |
| 24 May 2026 | Ivermectin | 5.8 | 25mg | 22.2mg | -11.2% | 99.34% | Lab B |
| 24 May 2026 | Salbutamol | 6.6 | 50mg | 52.7mg | +5.3% | 98.67% | Lab G |
| 24 May 2026 | Test Suspension | 6.4 | 200mg/ml | 207.9mg/ml | +4.0% | 99.52% | Lab F |
| 24 May 2026 | 4-Anilinopiperidine CAS 99918-43-1 | 4.3 | 5g | 5.4g | +8.2% | 96.69% | Lab G |
| 24 May 2026 | KPV Oral | 6.9 | 100mg | 96.6mg | -3.4% | 96.51% | Lab B |
| 24 May 2026 | PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 | 6.9 | 500g | 541.5g | +8.3% | 98.26% | Lab D |
| 24 May 2026 | Test Suspension | 5.3 | 100mg/ml | 109.4mg/ml | +9.4% | 95.28% | Lab D |
| 24 May 2026 | Test Suspension | 4.5 | 250mg/ml | 300.8mg/ml | +20.3% | 97.56% | Lab G |
| 23 May 2026 | 4-Anilinopiperidine CAS 99918-43-1 | 6.0 | 500g | 568.7g | +13.7% | 97.83% | Lab D |
| 23 May 2026 | APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 | 7.7 | 100g | 96.2g | -3.8% | 98.29% | Lab B |
| 23 May 2026 | CJC-1295 w/o DAC 10mg + IPA 10mg Blend | 6.6 | 50mg | 45.4mg | -9.2% | 99.11% | Lab E |
| 23 May 2026 | GHRP-2 Acetate | 6.9 | 50mg | 42.8mg | -14.3% | 96.88% | Lab G |
| 23 May 2026 | Hyaluronic acid | 5.3 | 20mg | 18.4mg | -8.0% | 99.67% | Lab B |
| 23 May 2026 | KPV Oral | 4.9 | 50mg | 50.4mg | +0.9% | 99.25% | Lab E |
| 23 May 2026 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 8.0 | 10mg | 11.4mg | +14.5% | 99.79% | Lab G |
| 23 May 2026 | Hyaluronic acid | 5.1 | 15mg | 15.3mg | +1.7% | 98.70% | Lab B |
| 23 May 2026 | IGF-1 LR3 | 5.3 | 15mg | 18.6mg | +24.3% | 96.82% | Lab F |
| 23 May 2026 | N-Acetyl Epitalon Amidate | 4.8 | 20mg | 20.2mg | +1.0% | 99.44% | Lab G |
| 21 May 2026 | HGH 191AA (Somatropin) | 7.3 | 15mg | 13.4mg | -10.8% | 97.16% | Lab B |
| 21 May 2026 | IGF-1 LR3 | 5.4 | 5mg | 5.4mg | +8.1% | 96.58% | Lab A |
| 21 May 2026 | NPP (N-phenethyl-4-piperidone) CAS 39742-60-4 | 7.1 | 5g | 5.7g | +14.6% | 97.02% | Lab A |
| 21 May 2026 | 17a-Methyl-1-Testosterone | 5.8 | 100mg | 95.3mg | -4.7% | 95.83% | Lab A |
| 21 May 2026 | 4-Anilinopiperidine CAS 99918-43-1 | 7.7 | 100g | 89.0g | -11.0% | 95.57% | Lab A |
| 21 May 2026 | Cagrilintide 5mg + Semaglutide 5mg Blend | 8.1 | 5mg | 5.5mg | +9.1% | 98.66% | Lab E |
| 21 May 2026 | IGF-1 LR3 | 5.8 | 30mg | 25.9mg | -13.5% | 97.17% | Lab A |
| 21 May 2026 | Ivermectin | 7.2 | 20mg | 18.2mg | -8.9% | 99.03% | Lab G |
| 21 May 2026 | NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend | 5.7 | 50mg | 53.6mg | +7.2% | 96.57% | Lab A |
| 21 May 2026 | PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 | 6.1 | 100g | 125.0g | +25.0% | 98.78% | Lab G |
| 21 May 2026 | Salbutamol | 7.7 | 50mg | 52.0mg | +4.0% | 98.58% | Lab E |
| 21 May 2026 | Test Suspension | 6.6 | 100mg/ml | 118.6mg/ml | +18.6% | 98.41% | Lab D |
| 20 May 2026 | 4-Anilinopiperidine CAS 99918-43-1 | 6.7 | 500g | 566.7g | +13.3% | 98.85% | Lab B |
| 20 May 2026 | Cagrilintide 5mg + Semaglutide 5mg Blend | 5.1 | 10mg | 12.2mg | +21.6% | 97.07% | Lab G |
| 20 May 2026 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 7.3 | 2mg | 1.8mg | -9.3% | 96.59% | Lab C |
| 20 May 2026 | Hyaluronic acid | 6.1 | 10mg | 11.6mg | +15.7% | 97.31% | Lab G |
| 20 May 2026 | Tesamorelin 11mg + Ipamorelin 6mg Blend | 7.0 | 20mg | 20.7mg | +3.5% | 99.56% | Lab F |
| 19 May 2026 | BPC 500mcg + TB500 500mcg Blend Oral | 5.2 | 100mg | 124.8mg | +24.8% | 96.61% | Lab F |
| 19 May 2026 | Cagrilintide 5mg + Semaglutide 5mg Blend | 6.8 | 30mg | 27.1mg | -9.8% | 95.53% | Lab F |
| 19 May 2026 | Cerebrolysin | 5.0 | 20mg | 18.3mg | -8.6% | 96.06% | Lab E |
| 19 May 2026 | DHB (1-Test Cyp) Oral | 6.4 | 20mg | 24.1mg | +20.7% | 98.21% | Lab D |
| 19 May 2026 | Ivermectin | 8.1 | 100mg | 110.9mg | +10.9% | 95.91% | Lab G |
| 17 May 2026 | Tirzepatide | 6.5 | 20mg | 22.1mg | +10.5% | 99.08% | Lab E |
| 17 May 2026 | 4-Anilinopiperidine CAS 99918-43-1 | 6.3 | 500g | 606.1g | +21.2% | 98.13% | Lab F |
| 29 Jan 2026 | 17a-Methyl-1-Testosterone | 5.6 | 50mg | 44.5mg | -11.1% | 97.65% | Lab C |
| 29 Jan 2026 | DNP | 5.8 | 100mg | 95.3mg | -4.7% | 98.18% | Lab C |
| 29 Jan 2026 | HGH 191AA (Somatropin) | 7.1 | 10mg | 11.9mg | +19.0% | 97.70% | Lab B |
| 29 Jan 2026 | KLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg | 5.2 | 30mg | 26.6mg | -11.2% | 99.07% | Lab D |
| 29 Jan 2026 | N-Acetyl Epitalon Amidate | 8.8 | 50mg | 50.7mg | +1.4% | 95.80% | Lab F |
| 29 Jan 2026 | N-Acetyl Epitalon Amidate | 5.5 | 10mg | 10.1mg | +1.3% | 99.92% | Lab F |
| 29 Jan 2026 | PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 | 7.5 | 500g | 619.3g | +23.9% | 98.81% | Lab A |
| 29 Jan 2026 | Tesamorelin 11mg + Ipamorelin 6mg Blend | 8.3 | 50mg | 49.1mg | -1.8% | 95.15% | Lab B |
| 26 Jan 2026 | Boldenone Undecylenate (EQ) Raw | 8.6 | 10g | 8.7g | -12.9% | 95.95% | Lab A |
| 26 Jan 2026 | Ivermectin | 6.4 | 100mg | 105.3mg | +5.3% | 98.14% | Lab C |
| 26 Jan 2026 | PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 | 5.8 | 5g | 4.6g | -7.5% | 99.18% | Lab D |
| 19 Jan 2026 | DNP | 7.2 | 10mg | 11.9mg | +18.8% | 95.24% | Lab E |
| 19 Jan 2026 | NAD+ 100mg + Mots-C 10mg + 5-Amino 1MQ 10mg Blend | 6.4 | 30mg | 27.6mg | -8.0% | 96.67% | Lab D |
| 19 Jan 2026 | Tesamorelin 11mg + Ipamorelin 6mg Blend | 7.9 | 50mg | 48.6mg | -2.7% | 99.94% | Lab D |
| 9 Jan 2026 | HGH 191AA (Somatropin) | 6.0 | 5mg | 4.4mg | -11.7% | 99.75% | Lab C |
| 9 Jan 2026 | Retatrutide Raw | 7.7 | 1g | 0.9g | -13.2% | 97.51% | Lab A |
| 7 Jan 2026 | DNP | 4.9 | 10mg | 9.4mg | -6.0% | 95.13% | Lab F |
| 7 Jan 2026 | P21 | 6.0 | 2mg | 2.2mg | +8.4% | 95.94% | Lab D |
| 7 Jan 2026 | Tesamorelin 11mg + Ipamorelin 6mg Blend | 9.2 | 5mg | 5.6mg | +11.2% | 96.06% | Lab G |
| 6 Jan 2026 | IGF-1 LR3 | 6.3 | 20mg | 22.2mg | +10.9% | 97.53% | Lab G |
| 6 Jan 2026 | N-Acetyl Epitalon Amidate | 5.4 | 10mg | 9.5mg | -4.6% | 98.78% | Lab F |
| 6 Jan 2026 | Retatrutide Raw | 5.5 | 500g | 496.3g | -0.7% | 98.06% | Lab B |
| 6 Jan 2026 | Vesugen | 9.1 | 20mg | 17.1mg | -14.7% | 98.71% | Lab A |
| 29 Dec 2025 | APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 | 8.2 | 100g | 123.2g | +23.2% | 98.66% | Lab F |
| 29 Dec 2025 | Boldenone Undecylenate (EQ) Raw | 8.3 | 100g | 91.1g | -8.9% | 99.40% | Lab F |
| 29 Dec 2025 | CJC-1295 w/o DAC 10mg + IPA 10mg Blend | 5.5 | 20mg | 18.8mg | -6.2% | 97.21% | Lab C |
| 29 Dec 2025 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 7.1 | 5mg | 5.2mg | +3.9% | 98.35% | Lab A |
| 29 Dec 2025 | Hyaluronic acid | 6.4 | 20mg | 20.0mg | -0.1% | 97.74% | Lab A |
| 29 Dec 2025 | IGF-1 LR3 | 5.1 | 2mg | 1.9mg | -2.5% | 99.33% | Lab B |
| 29 Dec 2025 | P21 | 5.8 | 2mg | 1.8mg | -12.4% | 99.54% | Lab G |
| 29 Dec 2025 | Vesugen | 6.5 | 50mg | 56.1mg | +12.3% | 95.41% | Lab B |
| 12 Dec 2025 | APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 | 5.8 | 500g | 575.8g | +15.2% | 95.19% | Lab F |
| 12 Dec 2025 | APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 | 6.6 | 10g | 12.5g | +24.8% | 97.10% | Lab C |
| 12 Dec 2025 | Cagrilintide 5mg + Semaglutide 5mg Blend | 6.8 | 5mg | 5.0mg | -0.5% | 95.41% | Lab G |
| 12 Dec 2025 | NPP (N-phenethyl-4-piperidone) CAS 39742-60-4 | 8.2 | 10g | 12.1g | +20.6% | 96.05% | Lab G |
| 12 Dec 2025 | PMK ethyl glycidate (3,4-MDP-2-P ethyl glycidate) CAS 28578-16-7 | 7.1 | 5g | 6.0g | +19.4% | 95.35% | Lab D |
| 12 Dec 2025 | Tesamorelin 11mg + Ipamorelin 6mg Blend | 6.3 | 2mg | 1.9mg | -6.1% | 98.54% | Lab F |
| 6 Dec 2025 | Retatrutide | 7.4 | 5mg | 5.07mg | +1.4% | 99.67% | Lab E |
| 6 Dec 2025 | Retatrutide | 8.0 | 20mg | 20.5mg | +2.5% | 99.95% | Lab E |
| 6 Dec 2025 | Retatrutide | 8.0 | 10mg | 10.4mg | +4.0% | 99.95% | Lab E |
| 5 Dec 2025 | Alprostadil | 7.0 | 15mg | 15.0mg | +0.0% | 98.96% | Lab A |
| 5 Dec 2025 | DNP | 6.4 | 20mg | 20.6mg | +2.9% | 95.35% | Lab A |
| 5 Dec 2025 | Nandrolone Decanoate (Deca) Raw | 9.0 | 100g | 88.6g | -11.4% | 99.35% | Lab A |
| 23 Nov 2025 | 17a-Methyl-1-Testosterone | 8.2 | 50mg | 48.1mg | -3.8% | 98.12% | Lab D |
| 23 Nov 2025 | BPC 500mcg + TB500 500mcg Blend Oral | 6.5 | 20mg | 17.9mg | -10.6% | 95.33% | Lab A |
| 23 Nov 2025 | DNP | 5.6 | 10mg | 9.6mg | -4.2% | 98.72% | Lab C |
| 23 Nov 2025 | N-Acetyl Epitalon Amidate | 5.5 | 20mg | 23.2mg | +15.8% | 98.70% | Lab D |
| 23 Nov 2025 | NPP (N-phenethyl-4-piperidone) CAS 39742-60-4 | 7.1 | 1g | 0.9g | -13.2% | 95.56% | Lab F |
| 23 Nov 2025 | Retatrutide Raw | 6.8 | 10g | 11.1g | +11.2% | 99.30% | Lab C |
| 17 Nov 2025 | BPC 500mcg + TB500 500mcg Blend Oral | 7.7 | 20mg | 21.1mg | +5.7% | 99.10% | Lab A |
| 17 Nov 2025 | HGH 191AA (Somatropin) | 7.1 | 2mg | 1.9mg | -4.0% | 96.78% | Lab F |
| 17 Nov 2025 | NPP (N-phenethyl-4-piperidone) CAS 39742-60-4 | 7.7 | 100g | 98.2g | -1.8% | 98.24% | Lab E |
| 14 Nov 2025 | 17a-Methyl-1-Testosterone | 6.5 | 20mg | 20.7mg | +3.3% | 96.01% | Lab C |
| 14 Nov 2025 | Boldenone Undecylenate (EQ) Raw | 9.2 | 100g | 94.7g | -5.3% | 95.35% | Lab E |
| 14 Nov 2025 | BPC 500mcg + TB500 500mcg Blend Oral | 5.1 | 50mg | 55.4mg | +10.8% | 98.83% | Lab D |
| 14 Nov 2025 | Vilon | 8.0 | 30mg | 32.1mg | +6.9% | 95.39% | Lab F |
| 5 Nov 2025 | Cerebrolysin | 5.5 | 15mg | 13.0mg | -13.1% | 97.71% | Lab E |
| 5 Nov 2025 | Ivermectin | 4.0 | 25mg | 21.4mg | -14.5% | 96.92% | Lab F |
| 5 Nov 2025 | Tesamorelin 11mg + Ipamorelin 6mg Blend | 6.8 | 10mg | 9.7mg | -2.5% | 99.42% | Lab D |
| 4 Nov 2025 | 17a-Methyl-1-Testosterone | 9.1 | 20mg | 20.4mg | +2.2% | 96.95% | Lab B |
| 4 Nov 2025 | 4-Anilinopiperidine CAS 99918-43-1 | 4.9 | 10g | 11.4g | +14.4% | 96.81% | Lab F |
| 4 Nov 2025 | Cerebrolysin | 6.2 | 2mg | 2.5mg | +25.0% | 99.91% | Lab D |
| 4 Nov 2025 | GHRP-2 Acetate | 9.2 | 15mg | 14.7mg | -1.7% | 98.39% | Lab B |
| 4 Nov 2025 | GHRP-2 Acetate | 8.4 | 5mg | 5.5mg | +10.1% | 98.46% | Lab E |
| 4 Nov 2025 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 7.5 | 5mg | 4.3mg | -14.3% | 95.76% | Lab B |
| 4 Nov 2025 | KPV Oral | 6.0 | 100mg | 119.6mg | +19.6% | 98.06% | Lab D |
| 4 Nov 2025 | NPP (N-phenethyl-4-piperidone) CAS 39742-60-4 | 5.9 | 100g | 119.8g | +19.8% | 95.80% | Lab E |
| 4 Nov 2025 | P21 | 8.5 | 20mg | 18.5mg | -7.4% | 99.99% | Lab C |
| 17 Oct 2025 | APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 | 6.6 | 10g | 9.4g | -5.9% | 96.49% | Lab B |
| 17 Oct 2025 | Hyaluronic acid | 6.5 | 50mg | 52.5mg | +5.0% | 95.90% | Lab C |
| 9 Oct 2025 | APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 | 6.6 | 5g | 6.1g | +21.0% | 95.58% | Lab A |
| 9 Oct 2025 | Cerebrolysin | 6.5 | 15mg | 13.8mg | -8.2% | 95.42% | Lab E |
| 9 Oct 2025 | Salbutamol | 6.5 | 100mg | 118.5mg | +18.5% | 96.80% | Lab G |
| 3 Oct 2025 | BPC-157 | 8.0 | 5mg | 4.92mg | -1.6% | 99.95% | Lab E |
| 3 Oct 2025 | Cagrilintide 5mg + Semaglutide 5mg Blend | 5.6 | 50mg | 49.9mg | -0.3% | 96.02% | Lab C |
| 3 Oct 2025 | IGF-1 LR3 | 6.5 | 10mg | 12.2mg | +22.1% | 98.13% | Lab D |
| 3 Oct 2025 | KLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg | 6.8 | 5mg | 4.7mg | -5.9% | 96.15% | Lab D |
| 3 Oct 2025 | N-Acetyl Epitalon Amidate | 6.6 | 5mg | 5.2mg | +5.0% | 95.85% | Lab D |
| 3 Oct 2025 | Vilon | 5.7 | 10mg | 9.1mg | -9.4% | 96.93% | Lab F |
| 16 Jul 2025 | Tirzepatide | 6.5 | 5mg | 5.47mg | +9.4% | 99.83% | Lab E |
| 10 Jul 2025 | BPC-157 | 5.6 | 5mg | 5.17mg | +3.4% | 98.57% | Lab A |